These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25652561)

  • 41. Assessing performance of sequential analysis methods for active drug safety surveillance using observational data.
    Zhou X; Bao W; Gaffney M; Shen R; Young S; Bate A
    J Biopharm Stat; 2018; 28(4):668-681. PubMed ID: 29157113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
    Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
    Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statistical methods for the analysis of adverse event data.
    Kieser M
    Pharm Stat; 2016 Jul; 15(4):290-1. PubMed ID: 27324410
    [No Abstract]   [Full Text] [Related]  

  • 44. The utilization and challenges of Japan's MID-NET
    Yamada K; Itoh M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Ishiguro C; Uyama Y;
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):601-608. PubMed ID: 30945387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 46. Electronic Health Data for Postmarket Surveillance: A Vision Not Realized.
    Moore TJ; Furberg CD
    Drug Saf; 2015 Jul; 38(7):601-10. PubMed ID: 26025018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.
    Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068
    [No Abstract]   [Full Text] [Related]  

  • 49. Is reporting rate a good predictor of risks associated with drugs?
    Pierfitte C; Bégaud B; Lagnaoui R; Moore ND
    Br J Clin Pharmacol; 1999 Mar; 47(3):329-31. PubMed ID: 10215758
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria.
    Hochberg AM; Hauben M
    Clin Pharmacol Ther; 2009 Jun; 85(6):600-6. PubMed ID: 19322165
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug-safety pilot makes the grade.
    Ledford H
    Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
    [No Abstract]   [Full Text] [Related]  

  • 53. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

  • 54. Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database.
    Florek AG; Nardone B; Thareja S; Tran G; Giles FJ; West DP
    Br J Dermatol; 2017 Nov; 177(5):e220-e221. PubMed ID: 28646575
    [No Abstract]   [Full Text] [Related]  

  • 55. Illusions of objectivity and a recommendation for reporting data mining results.
    Hauben M; Reich L; Gerrits CM; Younus M
    Eur J Clin Pharmacol; 2007 May; 63(5):517-21. PubMed ID: 17364192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?
    Pacurariu AC; Hoeve CE; Arlett P; Genov G; Slattery J; Sturkenboom MCJM; Straus SMJM
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):168-173. PubMed ID: 29278866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Common Models, Different Approaches.
    Gagne JJ
    Drug Saf; 2015 Aug; 38(8):683-6. PubMed ID: 26088718
    [No Abstract]   [Full Text] [Related]  

  • 58. US consumer group criticizes proposal to allow drug makers to challenge safety information.
    McCarthy M
    BMJ; 2015 Mar; 350():h1514. PubMed ID: 25784706
    [No Abstract]   [Full Text] [Related]  

  • 59. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007.
    Niu MT; Ball R; Woo EJ; Burwen DR; Knippen M; Braun MM;
    Vaccine; 2009 Jan; 27(2):290-7. PubMed ID: 18992783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Two UK Government proposals bearing on drug safety.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1997 Mar; 16(1):1-7. PubMed ID: 9192053
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.